PO.TB10.14 · 肿瘤生物学
肠道细菌作为胰腺癌进展中干性维持的隐形建筑师
Gut bacteria as hidden architects of stemness maintenance in the progression of pancreatic cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:胰腺导管腺癌(PDAC)是最致命的癌症之一,其特征是侵袭性的肿瘤微环境(TME)以及一小群驱动复发和治疗耐药的癌症干细胞(CSC)。有证据表明,从肠道迁移至胰腺的细菌重塑了TME,以维持这些CSC。尽管微生物失衡与其他癌症相关,但其在PDAC干性中的作用仍不明确。本研究探讨肠道来源微生物及其代谢产物如何重编程肿瘤微环境,从而富集CSC并加速PDAC进展。
方法:对PDAC患者样本进行临床分析,以鉴定导致菌群失调的多种微生物物种。我们采用16S rRNA FISH(荧光原位杂交)和脂多糖(LPS)染色进行组织验证,以定位这些细菌在人和小鼠PDAC组织中的分布。为明确微生物的作用,我们将PDAC细胞系和正常胰腺细胞系暴露于细菌上清、活菌或纯化的LPS,随后通过肿瘤球、连续稀释和集落实验进行功能验证,并采用免疫荧光、蛋白质印迹和qPCR评估CSC标志物。接下来,我们通过对细菌上清进行LC-MS分析以及对抗生素(Abx)处理小鼠进行RNA测序,应用组学整合来鉴定与CSC富集相关的微生物代谢产物和信号通路。在使用Kras LSL-G12D/+; Pdx1-Cre(KC)、Kras LSL-G12D/+; Trp53 R172H/+; Pdx1-Cre(KPC)以及经Abx处理的C57BL/6J(C57)小鼠开展的体内研究中,我们评估了微生物组耗竭如何重塑CSC动态和PDAC进展。
结果:对62例切除的PDAC样本进行的临床分析显示,基底样亚型富集了铜绿假单胞菌(Pseudomonas aeruginosa)、鲍曼不动杆菌(Acinetobacter baumannii)和大分子鞘氨醇单胞菌(Sphingopyxis macrogoltabida),将微生物菌群失调与肿瘤侵袭性联系起来。原位杂交和LPS染色揭示了细菌在人PDAC以及KC和KPC肿瘤中呈分期依赖性的积累。LPS或细菌上清升高了CSC和增殖标志物,包括SOX2、SOX9、NANOG、Cyclin A和p-ERK,而正常胰腺细胞则保持不变。与铜绿假单胞菌和大分子鞘氨醇单胞菌共培养产生了最强的干性诱导,并伴有LPS-CD44共定位。功能实验和KPC类器官证实了自我更新和生长的增强,以大分子鞘氨醇单胞菌上清最为显著。异种移植肿瘤中的Abx处理改变了肿瘤生长,KC和KPC小鼠表现出PanIN病变减少以及CD44和Ki67表达降低,这与CSC维持的丧失一致。
结论:PDAC微环境中的失调微生物组通过代谢产物介导的信号维持了CSC驱动的侵袭性。靶向这一微生物组-干性轴可能提供一种限制PDAC进展并改善患者预后的治疗策略。
查看英文原文 English abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, defined by an aggressive tumor microenvironment (TME) and a small pool of cancer stem cells (CSCs) that fuel recurrence and therapy resistance. Evidence suggests that bacteria migrating from the gut to the pancreas reshape the TME to sustain these CSCs. Although microbial imbalance is linked to other cancers, its role in PDAC stemness remains unclear. This study investigates how gut-derived microbes and their metabolites reprogram the tumor niche to enrich CSCs and accelerate PDAC progression.
Methodology: Clinical profiling of PDAC patient samples was performed to identify diverse microbial species that contribute to dysbiosis. We performed tissue validation using 16S rRNA FISH (fluorescent In-situ hybridization) and lipopolysaccharide (LPS) staining to localize these bacteria in human and murine PDAC tissues. To define microbial effects, we exposed PDAC and normal pancreatic cell lines to bacterial supernatants, live bacteria, or purified LPS, followed by functional validation through tumor sphere, serial dilution, and colony assays with CSC markers assessed by immunofluorescence, western blotting, and qPCR. We next applied Omics Integration using LC-MS of bacterial supernatants and RNA sequencing of Antibiotics (Abx) treated mice to identify microbial metabolites and signaling pathways linked to CSC enrichment. In our In-Vivo studies using Kras LSL-G12D/+; Pdx1-Cre (KC), Kras LSL-G12D/+; Trp53 R172H/+ ;Pdx1-Cre (KPC), and C57BL/6J (C57) mice treated with Abx, we evaluated how microbiome depletion reshapes CSC dynamics and PDAC progression.
Results: Clinical Profiling of 62 resected PDAC samples showed that the basal-like subtype is enriched with Pseudomonas aeruginosa, Acinetobacter baumannii , and Sphingopyxis macrogoltabida , linking microbial dysbiosis to tumor aggressiveness. In-situ hybridization and LPS staining revealed stage-dependent bacterial accumulation in human PDAC and in KC and KPC tumors. LPS or bacterial supernatants elevated CSC and proliferation markers including SOX2, SOX9, NANOG, Cyclin A, and p-ERK, while normal pancreatic cells remained unchanged. Co-culture with P.aeruginosa and S.macrogoltabida produced the strongest stemness induction with LPS-CD44 co-localization. Functional assays and KPC organoids confirmed enhanced self-renewal and growth, most pronounced with S.macrogoltabida supernatant. Abx treatment in xenograft tumors altered tumor growth, and KC and KPC mice showed reduced PanIN lesions with decreased CD44 and Ki67 expression, consistent with loss of CSC maintenance.
Conclusion: A dysbiotic microbiome within the PDAC microenvironment sustains CSC-driven aggressiveness through metabolite-mediated signaling. Targeting this microbiome-stemness axis may offer a therapeutic approach to limit PDAC progression and improve patient outcomes.
利益披露 Disclosure
K. Arikath, None..
S. Choi, None..
Z. W. Alsafwani, None..
P. Mathivanan, None..
P. Narayanasamy, None..
M. P. Ponnusamy, None.